2021 Deal Action In India: Watch Private Equity And E-Pharmacy

Pharma Deal Making Vibrant After 2020 COVID-19 Deals

Most roads led to India in 2020 when it came to deals to expand access to COVID-19 therapies, but the challenging year also saw significant private equity interest and there are expectations of more action ahead in the new year.

Sunset behind the President Residence, Rashtrapati Bhavan, New Delhi, India. — 2021 Is Expected To See More Deal Action In India • Source: Shutterstock

The overall deal-making environment may have been scarred by the pandemic in 2020, but Indian firms appeared to emerge as partners of choice for scaling up COVID-19 therapies and expanding access to these drugs.

While key COVID-19-related alliances grabbed headlines, the year gone by also saw significant private equity (PE) action in India. Things also heated up in the domestic e-pharmacy space, where there is likely more in store

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

AbbVie Pays $335m Up Front To Partner With ADARx On siRNA Therapeutics

14 May 2025

• By Mandy Jackson

ADARx CEO Zhen Li told Scrip the collaborators will advance novel siRNA medicines, but ADARx retains its clinical-stage and many preclinical programs and remains open to more deals.

Bluebird, Private Equity Firms Look To Sweeten Buyout Deal

14 May 2025

• By Alaric DeArment

Shareholders are being offered a flat fee of $5 per share as an alternative to $3 plus a contingent value right, which could be a more attractive option if they want cash up front.

Novo Nordisk Looks To Septerna For Oral Obesity Options

14 May 2025

• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.

GSK Pays $1.2bn For Phase III-Ready MASH Contender

14 May 2025

• By Andrew McConaghie

The acquisition of Boston Pharma’s once-a-month FGF21 analog adds to GSK’s liver disease portfolio.

Industry Leaders Grapple With Trump’s MFN Pricing Plan

14 May 2025

• By Jessica Merrill

At the Bank of America health care conference, pharma leaders speculated on what Trump’s executive order on drug pricing could mean for US and European drug prices.